Home › expression
 

Keywords :   


Tag: expression

Epson Expression Home XP-440 Small-in-One Printer

2017-09-22 18:06:17| PC Magazine Ink Jet Printers Product Guide

The Epson Expression Home XP-440 Small-in-One is one of the tiniest all-in-one printers in town, and delivers good text and graphics quality and solid speed to go with a basic feature set.

Tags: home printer expression epson

 

Epson Expression 12000XL-PH

2017-08-07 20:05:56| PC Magazine Scanners Product Guide

The Epson Expression 12000XL-PH is a large, tabloid-size graphics arts and photograph scanner that is compatible with a large array of media and produces excellent output.

Tags: expression epson

 
 

Epson Expression ET-2650 EcoTank All-in-One Printer

2017-06-19 12:07:34| PC Magazine Multi-Function Printers Product Guide

The Epson Expression ET-2650 All-in-One Printer may lack a few features for the price, but it prints quite well and very inexpensively.

Tags: printer expression epson epson printer

 

Epson Expression 12000XL Graphic Arts Scanner

2017-06-19 12:07:34| PC Magazine Scanners Product Guide

The Epson Expression 12000XL Graphic Arts Scanner produces high-quality scans of photos and illustrations at up to tabloid size.

Tags: arts expression graphic scanner

 

European Commission Approves KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations

2017-01-31 22:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: high positive cell treatment

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »